Profil bibliographique

Heidi Thomas

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

23Publications signalées

62Citations signalées

5Affiliations récentes

Les institutions déclarées

The University of Sydney The University of Western Australia Cooperative Trials Group for Neuro-Oncology Respiratory Clinical Trials National Health and Medical Research Council

Les domaines associés

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and ApplicationsBladder and Urothelial Cancer TreatmentsEthics in Clinical Research

Les publications récentes

Accès ouvert 2026 article OpenAlex

Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials

Christopher J. Sweeney, Vrishab Krishna, Viswesh Krishna, Akshay Neema et autres

au, us, nl (code pays fourni par la source)

1 citation JCO Precision Oncology

Accès ouvert 2026 article OpenAlex

AI-Based Pathology Classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial

Sebastian Medina, Naoto Tokuyama, Vaishnavi Putcha, Tilak Pathak et autres

us, au (code pays fourni par la source)

0 citations Clinical Cancer Research

Accès ouvert 2026 article OpenAlex

What’s the point? Variation and innovation of Neolithic arrowhead technology in northwest Arabia

Finn Stileman, Jane McMahon, Ceri Shipton, Roman H. Bamping et autres

gb, au, sa (code pays fourni par la source)

0 citations Journal of Archaeological Science Reports

2026 conference-abstract OpenAlex

Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.

Christopher Sweeney, J Proudfoot, Simranjeet Kaur, Darby Thompson et autres

au, us, gb (code pays fourni par la source)

1 citation Journal of Clinical Oncology

2026 conference-abstract OpenAlex

An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).

Sebastian R. Medina, Naoto Tokuyama, Vaishnavi Putcha, Tilak Pathak et autres

us, au (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 letter OpenAlex

Reply to Daoyuan Li’s Words of Wisdom re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.011

Dickon Hayne, Alison Y. Zhang, Heidi Thomas, Andrew D. Redfern et autres

au (code pays fourni par la source)

0 citations European Urology

2026 letter OpenAlex

Reply to Tonghu Liu’s Letter to the Editor re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette Guérin–naïve Non–Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.009

Dickon Hayne, Alison Y. Zhang, Heidi Thomas, Andrew D. Redfern et autres

au (code pays fourni par la source)

0 citations European Urology Focus

2026 article OpenAlex

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam et autres

au, nz, ca, us (code pays fourni par la source)

3 citations Nature Cancer

2026 article OpenAlex

177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer

Narjess Ayati, Nathan Papa, Megan Crumbaker, Shalini Subramaniam et autres

au, Afrique du Sud, us, ir, de, nl, it, es (code pays fourni par la source)

2 citations Radiology

2025 article OpenAlex

2394P Circulating tumour cell (CTC) characteristics associated with survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) in a randomised trial of enzalutamide with or without [177Lu]Lu-PSMA-617 (ENZA-p; ANZUP 1901)

Megan Crumbaker, S. Gupta, Nathan Papa, N Hartmann et autres

au, us (code pays fourni par la source)

0 citations Annals of Oncology

2025 conference-abstract OpenAlex

LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)

P.L. Nguyen, C. Sweeney, M.R. Stockler, Heidi Thomas et autres

us, au, nz, gb, ie, at, de (code pays fourni par la source)

12 citations Annals of Oncology

Accès ouvert 2025 article OpenAlex

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

gb, it (code pays fourni par la source)

5 citations JAMA Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.